Medical Advocates
HIV Infection/Disease
 
Facial Lipoatrophy Injection
Treatment
 
General Reports
Calcium Hydroxylapatite
 Fat
Hyaluronic Acid
Polylactic Acid
Polyalkylimide Gel
Silicone


 

 
HIV Facial Lipoatrophy Treament   Main New/Newsworthy Home Page  
Last Update:
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

General Reports
       
         Journal Papers, Abstracts, and Commentaries
 
  A WEEK-IN-REVIEW FEATURED REPORT
 Reconstructive treatment for antiretroviral-associated facial lipoatrophy: a prospective
study comparing autologous fat and synthetic substances.
 Negredo E, Higueras C, Adell X, et al 
AIDS Patient Care STDS. 2006 Dec;20(12):829-37.
 Abstract

Calcium Hydroxylapatite
       
         Journal Papers, Abstracts, and Commentaries
 
  Calcium Hydroxylapatite for Facial Rejuvenation.
 Berlin A, Cohen JL, Goldberg DJ.  
 Semin Cutan Med Surg. 2006 Sep;25(3):132-137.
 Abstract

Fat  

       

        Journal Papers, Abstracts, and Commentaries
 
  Treatment of facial fat atrophy related to treatment with protease inhibitors by
"autologous fat injection in patients with human immunodeficiency virus infection.
Serra-Renom JM, Fontdevila J. 
Plast Reconstr Surg. 2004 Aug;114(2):551-5.
 Abstract
 
Treatment of human immunodeficiency virus-associated lipodystrophy with
dermafat graft transfer to the malar area.
Strauch B, Baum T, Robbins N.
 Plast Reconstr Surg. 2004 Jan;113(1):363-70
 Abstract

Hyaluronic Acid

       
          Journal Papers, Abstracts, and Commentaries
 
  Hyaluronic acid treatment of facial fat atrophy in HIV-positive patients.
Bugge H, Negaard A, Skeie L, Bergersen B.
HIV Med. 2007 Nov;8(8):475-82.
 Abstract

Polylactic Acid
       

               News

  The Food and Drug Administration  approves Sculptra, an injectable filler to correct
facial fat loss in people with human immunodeficiency virus (HIV) on August 3, 2004,
August 03, 2004
 News Release

              Journal Papers, Abstracts, and Commentaries
 
 
Treatment of HIV lipoatrophy and lipoatrophy of aging with poly-L-lactic acid: A prospective 3-year
follow-up study.
Levy RM, Redbord KP, Hanke CW.
J Am Acad Dermatol. 2008 Dec;59(6):923-933.
 Abstract
 
Polylactic acid injections: usefullness for the treatment of facial lipoatrophy in HIV+
patients under tritherapy.
Piquet M, Brignol L, Chatelain B, Rey D, et al 
Rev Stomatol Chir Maxillofac. 2007 Jul 31;
Abstract
 
Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial
lipoatrophy.
Moyle G, Brown S, Lysakova L, Barton S.
HIV Med. 2006 Apr;7(3):181-5.
 Abstract
 
Use of polylactic Acid implants to correct facial lipoatrophy in human immunodeficiency
virus 1-positive individuals receiving combination antiretroviral therapy.
 Cattelan AM, Bauer U, Trevenzoli M, et al
Arch Dermatol. 2006 Mar;142(3):329-34. R
 Abstract
 
Deep Subcutaneous Application of Poly-L-Lactic Acid as a Filler for Facial Lipoatrophy in
HIV-Infected Patients.
 Borelli C, Kunte C, Weisenseel P, et al
Skin Pharmacol Physiol. 2005 Aug 19;18(6):273-278
 Abstract
 
Poly-L-lactic Acid as a facial filler.
Sterling JB, Hanke CW.
Skin Therapy Lett. 2005 Jun;10(5):9-11.
 Abstract
 
Treatment of Facial Lipoatrophy With Intradermal Injections of Polylactic Acid in
HIV-Infected Patients.
 Lafaurie M, Dolivo M, Porcher R, et al  
J Acquir Immune Defic Syndr. 2005 Apr 1;38(4):393-398.
 Abstract
 
Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-
associated facial lipoatrophy.
 Burgess CM, Quiroga RM.  
J Am Acad Dermatol. 2005 Feb;52(2 Pt1):233-9
 Abstract

A randomized open-label study of immediate versus delayed polylactic acid
injections for the cosmetic management of facial lipoatrophy in persons with
HIV infection.
 Moyle G, Lysakova L, Brown S, et aL 
HIV Med. 2004 Mar;5(2):82-87.
 Abstract
 
  Polylactic acid implants (New-Fill)(R) to correct facial lipoatrophy in HIV-infected
patients: results of the open-label study VEGA.
Valantin MA, Aubron-Olivier C, Ghosn J, et al 
AIDS. 2003 Nov 21;17(17):2471-7
 Abstract
 
             Conference Reports, Abstracts, and Posters
 
 
Treatment of HIV-Related Facial Lipoatrophy: Incidence of Subcutaneous Papules Resulting
from Polylactic Acid Treatment Decreases with Facial Massage
 P. UNEMORI , C. EDEN  M. CONANT
(45 ICAAC)
 Abstract
 
Psychological assessment of HIV-infected patients with facial lipoatrophy
before and after reparatory treatment
CR Fumaz, JA Muņoz-Moreno, M J Ferrer, et al
(15IAC)
 Abstract
 

Polyalkylimide Gel

       
              Journal Papers, Abstracts, and Commentaries
 
  Long-Term Effect of Polyalkylimide Gel Injections on Severity of Facial Lipoatrophy and Quality of Life of
HIV-Positive Patients.
Kari.m RB, de Lint CA, van Galen SR, et al
 Aesthetic Plast Surg. 2008 Jun 13
 Abstract
 
             Conference Reports, Abstracts, and Posters
 
  Four year-experience of polyacrylamide gel (Aquamid) for facial lipoatrophy treatment
 E. Negredo, J. Puig, N. Perez, et al\
 (XVII International AIDS Conference)
 Abstract

Silicone
       

              Journal Papers, Abstracts, and Commentaries
 
  A Case of HIV-Associated Facial Lipoatrophy Treated With 1000-cs Liquid
Injectable Silicone.
Orentreich D, Leone AS.
Dermatol Surg. 2004 Apr;30(4):548-51.
 Abstract

HIV Facial Lipoatrophy Treament   Main New/Newsworthy Home Page  

Facial Lipoatrophy Injection Treatment